1)日本消化器病学会〔編(協力学会:日本肝臓学会)〕:NAFLD/NASH診療ガイドライン2014.南江堂,2014
2)日本肝臓学会(編):NASH・NAFLDの診療ガイド2015.文光堂,2015
3)Matteoni CA, et al:Nonalcoholic fatty liver disease;A spectrum of clinical and pathological severity. Gastroenterology 116:1413-1419, 1999
4)Chalasani N, et al:The diagnosis and management of nonalcoholic fatty liver disease;Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328-357, 2018
5)European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO):EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64:1388-1402, 2016
6)Angulo P, et al:Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149:389-397.e10, 2015
7)Hagström H, et al:Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67:1265-1273, 2017
8)Dulai PS, et al:Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease;Systematic review and meta-analysis. Hepatology 65:1557-1565, 2017